[Diet & Weight Loss Clinic] Could GLP-1 Drugs Even Suppress Cancer Progression?

Could GLP-1 Drugs Also Suppress Cancer Progression?

A Professional Review of the Emerging “Anti-Tumor Effect” Suggested by the Latest Medical Data

Published: 2026.05.25Supervised by: Shinya Ichimura, Chairman, Yokohama Front Neurosurgery & Urology ClinicOperated by: Kazunari Kaneda, CEO, Doctor Agent

Conclusion

GLP-1 receptor agonists are currently widely used for the treatment of type 2 diabetes and obesity. However, in recent years, growing global attention has focused on their potential ability to create a “less cancer-promoting internal environment” through mechanisms such as:

• Suppression of cancer cell proliferation

• Reduction of metastatic risk

• Suppression of chronic inflammation

• Improvement of insulin-related metabolic abnormalities

• Reduction of obesity-related cancer risk

Particularly between 2024 and 2025, a rapid increase in reports has emerged from:

• Epidemiological data involving over 1.1 million patients

• Integrated analyses of 67 clinical studies

• Molecular and cellular basic science research

These studies suggest a possible anti-tumor role for GLP-1 therapies.

However, one critical point must be emphasized:

GLP-1 drugs are not anti-cancer medications.

At present, they are being studied for their potential association with cancer prevention and suppression of progression, and the medical community continues to evaluate these findings cautiously.

What Is GLP-1?

GLP-1 (Glucagon-Like Peptide-1) is a hormone secreted from the small intestine after meals.

Its major physiological effects include:

• Lowering blood glucose levels

• Suppressing appetite

• Prolonging satiety

• Delaying gastric emptying

• Regulating insulin secretion

Today, GLP-1 therapies are used worldwide for:

• Type 2 diabetes

• Obesity

• Metabolic syndrome

Representative GLP-1 medications include:

• Ozempic

• Wegovy

• Mounjaro

• Rybelsus

Why Is GLP-1 Attracting Attention in Cancer Research?

Recent studies have clarified that:

• Obesity

• Hyperinsulinemia

• Chronic inflammation

are deeply associated with cancer development and progression.

This relationship is particularly strong in cancers such as:

• Colorectal cancer

• Breast cancer

• Liver cancer

• Pancreatic cancer

• Prostate cancer

• Endometrial cancer

Because GLP-1 therapies improve these metabolic and inflammatory conditions, they may help create an internal environment in which cancer cells are less likely to thrive.

Three Mechanisms by Which GLP-1 May Suppress Cancer Progression

1. Suppression of Cancer Cell “Growth Switches”

Recent molecular studies suggest that GLP-1 may influence intracellular signaling pathways involved in tumor growth, including:

• PI3K/AKT

• mTOR

• MAPK

These pathways function as signals telling cancer cells to continue proliferating.

GLP-1 may help interrupt these signals.

Some studies have also demonstrated:

• Induction of apoptosis (programmed cell death)

• Cell cycle arrest

2. Cutting Off the Cancer Cell Energy Supply

Cancer cells consume large amounts of glucose.

Additionally:

• Hyperglycemia

• Hyperinsulinemia

• Insulin resistance

are believed to promote tumor growth.

GLP-1 therapies contribute to:

• Blood glucose stabilization

• Weight reduction

• Suppression of excessive insulin secretion

thereby creating a metabolic environment less favorable for tumor growth.

3. Suppression of Chronic Inflammation

Chronic inflammation is a major driver of cancer progression.

Persistent inflammation can lead to:

• DNA damage

• Angiogenesis

• Immune evasion

• Metastatic promotion

GLP-1 therapies have been reported to potentially suppress inflammatory cytokines such as:

• TNF-α

• IL-6

• CRP

This may contribute to a biological environment that reduces metastatic potential.

The Shocking Findings From a 1.1 Million Patient Analysis

In 2024, a large-scale U.S. analysis involving more than 1.1 million obese patients reported lower risks of progression in cancers including:

• Breast cancer

• Gastrointestinal cancers

• Prostate cancer

Some findings suggested approximately:

Up to a 30% reduction in progression risk

This generated significant global attention.

2025: Emerging Evidence on Metastasis Suppression

In 2025, an integrated analysis of:

• Approximately 200,000 patients

• 67 clinical studies

reported that GLP-1 receptor agonists may reduce the risk of distant metastasis.

Researchers particularly focused on associations involving:

• Inflammation control

• Improvement of immune microenvironments

• Metabolic normalization

Does GLP-1 Cause Thyroid Cancer?

This is one of the most frequently asked questions.

The conclusion at present is:

No clear increase in thyroid cancer risk has been proven in humans.

The concern originated from earlier rodent studies.

However, researchers now understand that:

• Human and rodent thyroid structures differ significantly

• GLP-1 receptor distribution is different between species

In fact, large-scale human clinical datasets involving hundreds of thousands of patients have not demonstrated a definitive increase in cancer incidence.

Who Should Still Use Caution?

Even today, GLP-1 therapies are generally avoided or used cautiously in individuals with:

• Medullary thyroid carcinoma

• MEN2 (Multiple Endocrine Neoplasia Type 2)

• Relevant family history of these conditions

This reflects the principle of prioritizing patient safety.

Could GLP-1 Become the Future of Cancer Prevention Medicine?

The medical field is increasingly recognizing that:

“Obesity treatment may itself become cancer prevention.”

Obesity is not merely a cosmetic issue.

It contributes to systemic harm through:

• Chronic inflammation

• Hyperinsulinemia

• Hormonal imbalance

• Cytokines released from adipose tissue

In other words:

Improving metabolism itself may become an anti-cancer strategy.

GLP-1 therapies are now being viewed as one of the central approaches in this evolving field.

Our Perspective

GLP-1 therapies can be highly effective when used appropriately.

However, misuse also carries risks.

Improper self-administration through social media recommendations or personal importation may lead to:

• Severe nausea

• Gallstones

• Pancreatitis

• Nutritional deficiencies

• Muscle mass loss

Therefore, professional management is essential, including:

• Blood testing

• Medical history evaluation

• Cancer risk assessment

• Thyroid disease screening

• Body composition monitoring

Who Should Consider Consultation?

You may benefit from medical consultation if you:

• Are concerned about obesity and future health risks

• Want to improve diabetes management

• Have a family history of cancer

• Wish to reduce visceral fat

• Want to extend healthy lifespan

• Seek medically supervised weight management

Summary

GLP-1 therapies are not simply “weight-loss drugs.”

Recent studies increasingly suggest possible associations with:

• Suppression of cancer progression

• Reduction of metastatic risk

• Improvement of chronic inflammation

• Metabolic normalization

In the future, obesity treatment and cancer prevention may become even more closely connected.

Building a healthier metabolic state may represent one of the most important steps toward reducing future disease risk.

If you are interested, consultation with a qualified medical professional is strongly recommended.

References

• Lucente D, et al. (2025)

  
  

  Comprehensive review on GLP-1-mediated suppression of tumor growth signaling and induction of apoptosis

• Levy S, et al. (2024)

  
  

  Large-scale U.S. analysis of 1.1 million obese patients examining GLP-1 therapies and reduced cancer progression risk

• Hsu CW, et al. (2025)

  
  

  Integrated analysis of 67 studies involving approximately 200,000 patients investigating metastasis suppression by GLP-1 receptor agonists

• Lin A, et al. (2025)

  
  

  Analysis of links between insulin resistance improvement, chronic inflammation control, and tumor suppression mechanisms